Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Multicenter, Open-label, Phase I/II Trial of Allo-QuadCAR01-T, an Allogeneic CAR-T-cell Therapy Targeting CD19 and CD20, for the Treatment of Relapsed or Refractory B-cell Malignancies

NCT07284433 is registered in ClinicalTrials.gov with AvenCell Therapeutics, Inc. as lead sponsor.

NCT NCT07284433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07284433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Multicenter, Open-label, Phase I/II Trial of Allo-QuadCAR01-T, an Allogeneic CAR-T-cell Therapy Targeting CD19 and CD20, for the Treatment of Relapsed or Refractory B-cell Malignancies
Lead sponsor
AvenCell Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 6, 2026
Completion date
November 2, 2029
Enrollment
178 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia and lymphoma, leukemia relapse, lymphoma diffuse large b-cell, lymphoma receiving car-t therapy